Panel Discussion: Equity, Diversity & Inclusion: How to Ensure Successful Enrolment of Under- Represented Communities in Oncology & Non-Oncology Indications

Time: 10:20 am
day: Day One


  • What are the key bottlenecks to engage with all patient communities and to ensure successful enrolment of under-represented?
  • How can we measure success in precision medicine clinical trials from the ED&I lens?
  • What role different stakeholders (regulators, drug developers, CDx developers) can all play to improve ED&I in precision medicine clinical trials?